R

Roche

Global pharmaceuticals and diagnostics company

Medical Director - CVM

Full-TimeUpdated on 10/15/2026
No salary listed
Mid
MD
Beijing, China+1 moreMore locations: Shanghai, China
In PersonUp to 30% global travel.
Biology & Biotech

About the job

Requirements
  • An M.D. is required.
  • Therapeutic knowledge in metabolism, obesity, and diabetes, with relevant clinical, scientific, and clinical trial or development experience, is required.
  • At least 2 years of post-graduate academic or clinical experience is required.
  • Experience applying data analysis and interpretation principles and techniques, including assessing clinical relevance, is required.
  • Knowledge of medical aspects of Good Clinical Practice, International Council for Harmonisation guidelines, the FDA, EMA, and other relevant guidelines and regulations is preferred.
  • Academic or teaching background is preferred.
  • Experience publishing scientific study results in a peer-reviewed journal is preferred.
  • Must be able to travel globally up to 30%.
  • Must demonstrate ethical conduct and Roche Values.
  • Must have working knowledge of the pharmaceutical or biotechnology industry and the functions and roles involved in drug development.
  • Must be able to prioritize multiple tasks and goals, completing them on time, on target, and within budget.
  • Must have interpersonal, verbal communication, influencing, and written communication skills.
  • Must have business presentation skills and be comfortable presenting internally and externally, staying focused, and raising challenges productively.
  • Must have negotiation skills to complete deliverables effectively with internal and external partners.
  • Must be able to make trade-off decisions while balancing ethics and efficacy.
  • Must demonstrate a strong orientation to teamwork.
Responsibilities
  • Participate in developing the clinical development plan for assigned molecules or indications.
  • Gather and analyze data and information needed to create the clinical development plan.
  • Work with Clinical Science Team members and relevant sub-teams to develop clinical development plan components, including analytics and data strategy, key opinion leader development, and publication strategy.
  • Work with the Clinical Science Team and other relevant teams to develop and provide information and input for the budget and resource requirements needed to implement the clinical development plan.
  • Monitor internal and external developments, trends, and dynamics relevant to clinical development to maintain a current perspective on influences and implications for assigned therapeutic and disease areas.
  • Participate in competitive intelligence and other market or industry assessment activities and projects as appropriate.
  • Maintain high standards of scientific and clinical knowledge in assigned therapeutic and disease areas.
  • Collaborate with internal and external partners and stakeholders, including clinical investigators, clinicians, scientists, key opinion leaders, and multidisciplinary groups in development, research, business development, commercial operations, and legal functions.
  • Provide clinical science input and guidance in meetings and reviews concerning early development and Phase I studies as appropriate, including reviewing and providing late-stage input on Phase I and II protocols.
  • Support internal partners in transitioning new drugs and indications into Medical Affairs studies, including contributing to Medical Affairs study protocol development.
  • Participate in the design, development, and execution of clinical studies.
  • Collaborate on developing product safety profiles and clinical sections of investigator brochures, presentations, and other materials.
  • Guide and advise others on identifying and selecting external investigators and study sites as appropriate.
  • Participate in developing and implementing communications strategies for ongoing and completed studies, including investigator meetings, key opinion leader interactions, advisory boards, major medical meetings, congresses, publications, and other materials.
  • Participate in developing and delivering internal and external presentations that convey the clinical development perspective and provide updates on strategies, plans, and activities, including presentations at advisory boards and other external forums representing Roche.
  • Collaborate on developing study analytics and data management plans.
  • Participate in ongoing reviews of medical and safety data.
  • Collaborate with relevant team members to measure and monitor study progress against objectives and plans, identify variances, and communicate issues, challenges, and potential resolution strategies.
  • Collaborate with relevant team members to ensure timely completion of interim study reporting.
  • Collaborate with relevant team members and clinical operations to close out clinical studies, secure data, and complete study reporting.
  • Support team members in ensuring correct medical and scientific data interpretation for interim and final study reporting.
  • Act as a medical monitor for assigned studies.
  • Participate in the relevant Clinical Science Team and as a standing or ad hoc member of relevant sub-teams, such as Study Management Teams, supporting cross-functional integration, coordination, and alignment for effective clinical development plan execution.
  • Support training of new Clinical Science Team members and, as appropriate, support relevant sub-teams in assigning and training new team members.
  • Support other Clinical Science Team members in developing briefing packages and responses to health authority questions by providing clinical science information and input.
  • Participate in health authority interactions as appropriate, under supervision from more experienced Medical Directors.
  • Support Clinical Science Team members, regulatory partners, and other stakeholders in completing and submitting regulatory filings and documentation; provide clinical science input for submissions and processes, including label and packaging language.
  • Contribute to scientific discussion in the local site community and provide study or program updates to the wider community.
Desired Qualifications
  • Academic or teaching background.
  • Experience publishing scientific study results in a peer-reviewed journal.
  • Knowledge of medical aspects of Good Clinical Practice, International Council for Harmonisation guidelines, the FDA, EMA, and other relevant guidelines and regulations.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.